PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis-Reference-Cited by-同舟云学术

PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis

Published:2019-09 Issue:5 Volume:20 Page:363-369.e2
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Téglási Vanda,Pipek Orsolya,Lózsa Rita,Berta Kinga,Szüts Dávid^ORCID,Harkó Tünde,Vadász Pál,Rojkó Lívia,Döme Balázs,Bagó Attila G.,Tímár József^ORCID,Moldvay Judit,Szállási Zoltán,Reiniger Lilla

Funder

Hungarian Brain Research Program

Breast Cancer Research Foundation

Novo Nordisk Foundation

Hungarian National Research,Development and Innovation Office

Hungarian Science Foundation

Hungarian National Research, Development and Innovation (NRDI) Office

Austrian Science Fund

Hungarian NRDI Office

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference54 articles.

1. Updates in the management of brain metastases;Arvold;Neuro Oncol,2016

2. Epidemiology of brain metastases;Nayak;Curr Oncol Rep,2012

3. Prevention of brain metastases;Bovi;Front Neurol,2018

4. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase–positive (ALK+) non–small-cell lung cancer: CNS efficacy results from the ALEX study;Gadgeel;Ann Oncol,2018

5. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients;Davies;Curr Med Res Opin,2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

2. Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods;Heliyon;2024-02

3. Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy;Translational Lung Cancer Research;2023-10

4. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases;Lung Cancer;2023-10

5. Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites;Modern Pathology;2023-09